A method of profiling bacterial growth time in the gut’s microbiome has been shown to be a rudimentary diagnostic tool for IBS and diabetes type II. A research team came together from the labs of Dr Elinav and Professor Segal to investigate at the Weizmann Institute of Science, Israel.
The millions of bacteria living within our gastrointestinal (GI) tract form a vast interactive community. It functions at as complex a level as any ecosystem might on the macro-scale. For this reason, we refer to such micro-communities as a microbiome; a topic of much interest in recent years with regards to studying various diseases.
Labiotech investigated the growing significance of the microbiome industry earlier this year, in particular in relation to the study of diseases such as Diabetes type II and Irritable bowl syndrome (IBS).
The Weizmann Institute of Science, a public research university in Rehovot, Israel, published a study in Science looking at how the growth time of particular bacterial colonies can in fact uniquely vary if you have a particular disease.